New drugs and combinations in the palliative treatment of colon and rectal cancer

Colorectal cancer (CRC) is a common disease. The overall survival has improved only marginally in recent decades despite advances in surgery and early detection. Potentially curative resection at disease presentation can be performed only in 70–80% of the patients, and overall survival at 5 years is...

Full description

Saved in:
Bibliographic Details
Published in:European journal of surgical oncology 2001-09, Vol.27 (6), p.595-600
Main Authors: Beretta, G.D., Pessi, M.A., Poletti, P., Mosconi, S., Labianca, R.
Format: Article
Language:English
Subjects:
Administration, Oral
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Biological and medical sciences
Chemotherapy
Clinical Trials as Topic
colorectal cancer
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - mortality
Colorectal Neoplasms - pathology
DNA Topoisomerases, Type I - analysis
Female
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Male
Medical sciences
Neoplasm Staging
Palliative Care - methods
Pharmacology. Drug treatments
Platinum Compounds - administration & dosage
Prognosis
Sensitivity and Specificity
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Survival Analysis
Tegafur - administration & dosage
Thymidylate Synthase - administration & dosage
Thymidylate Synthase - antagonists & inhibitors
Topoisomerase I Inhibitors
Tumors
Uracil - administration & dosage
Uracil - analogs & derivatives
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Colorectal cancer (CRC) is a common disease. The overall survival has improved only marginally in recent decades despite advances in surgery and early detection. Potentially curative resection at disease presentation can be performed only in 70–80% of the patients, and overall survival at 5 years is less than 60%. Advanced disease is associated with a poor prognosis. Treatment for advanced colorectal cancer has nevertheless made progress in the last few years. Systemic chemotherapy doubles the survival of these patients compared to untreated controls. Chemotherapy has demonstrated effective palliation, improvement of quality of life (QoL) and symptom improvement in such patients. For nearly four decades, fluorouracil (5FU) has been the mainstay of treatment. New compounds active against colorectal cancer are now available. Several studies on this topic are ongoing.
ISSN:0748-7983
1532-2157
DOI:10.1053/ejso.2001.1128